The addition of sitagliptin to ongoing metformin therapy significantly improves glycemic control in Chinese patients with type 2 diabetes.
about
Systematic review and meta-analysis of efficacy and safety of combinational therapy with metformin and dipeptidyl peptidase-4 inhibitorsThe clinical application of linagliptin in AsiansRisk of diarrhea in patients with type 2 diabetes mellitus treated with sitagliptin: a meta-analysis of 30 randomized clinical trialsCardiovascular Safety of Dipeptidyl-Peptidase IV Inhibitors: A Meta-Analysis of Placebo-Controlled Randomized Trials.Dipeptidyl peptidase-4 inhibitors and the risk of heart failure: a systematic review and meta-analysis.Comparative analysis of therapeutic efficiency and costs (experience in Bulgaria) of oral antidiabetic therapies based on glitazones and gliptins.Differential HbA1c response in the placebo arm of DPP-4 inhibitor clinical trials conducted in China compared to other countries: a systematic review and meta-analysis.Cardiovascular safety of sitagliptin in patients with type 2 diabetes mellitus: a pooled analysis.Efficacy and safety of canagliflozin in patients with type 2 diabetes mellitus from India.The placebo response of injectable GLP-1 receptor agonists vs. oral DPP-4 inhibitors and SGLT-2 inhibitors: a systematic review and meta-analysisEfficacy and safety of liraglutide versus sitagliptin, both in combination with metformin, in Chinese patients with type 2 diabetes: a 26-week, open-label, randomized, active comparator clinical trial.Sitagliptin: a review of its use in patients with type 2 diabetes mellitus.Meta-analysis of the cardiovascular outcomes with dipeptidyl peptidase 4 inhibitors: validation of the current FDA mandate.The safety of dipeptidyl peptidase-4 (DPP-4) inhibitors or sodium-glucose cotransporter 2 (SGLT-2) inhibitors added to metformin background therapy in patients with type 2 diabetes mellitus: a systematic review and meta-analysis.The Place of Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes Therapeutics: A "Me Too" or "the Special One" Antidiabetic Class?NRF2 activation by antioxidant antidiabetic agents accelerates tumor metastasis.Factors Related to the Glucose-Lowering Efficacy of Dipeptidyl Peptidase-4 Inhibitors: A Systematic Review and Meta-Analysis Focusing on Ethnicity and Study Regions.Evaluating the costs of glycemic response with canagliflozin versus dapagliflozin and empagliflozin as add-on to metformin in patients with type 2 diabetes mellitus in the United Arab Emirates.Adverse effects of incretin-based therapies on major cardiovascular and arrhythmia events: meta-analysis of randomized trials.Efficacy, safety and impact on β-cell function of dipeptidyl peptidase-4 inhibitors plus metformin combination therapy in patients with type 2 diabetes and the difference between Asians and Caucasians: a meta-analysis.Safety and tolerability of sitagliptin in type 2 diabetes: pooled analysis of 25 clinical studies.Safety of sitagliptin in elderly patients with type 2 diabetes: a pooled analysis of 25 clinical studies.Efficacy and safety of dipeptidyl peptidase-4 inhibitors and metformin as initial combination therapy and as monotherapy in patients with type 2 diabetes mellitus: a meta-analysis.A randomized clinical trial of the safety and efficacy of sitagliptin in patients with type 2 diabetes mellitus inadequately controlled by acarbose alone.Efficacy and safety of gemigliptin, a dipeptidyl peptidase-4 inhibitor, in patients with type 2 diabetes mellitus inadequately controlled with combination treatment of metformin and sulphonylurea: a 24-week, multicentre, randomized, double-blind, plRandomized trial assessing the safety and efficacy of sitagliptin in Chinese patients with type 2 diabetes mellitus inadequately controlled on sulfonylurea alone or combined with metformin.A randomized clinical trial evaluating the safety and efficacy of sitagliptin added to the combination of sulfonylurea and metformin in patients with type 2 diabetes mellitus and inadequate glycemic control.Racial and Ethnic Disparities in Prevalence and Care of Patients With Type 2 Diabetes.
P2860
Q26772081-DC07BE4B-4D5F-4DE8-B66F-5BFAAFCD9F92Q26781942-3D111276-B01F-44F9-A04C-2D9CCA4C15E7Q28544980-B6293A09-99C2-4B61-AEFC-F0E6D1D75401Q30240823-14B839E7-4AFB-4241-B9A5-8FD2BEE9F1EAQ30846870-2869CC7E-1F9A-41C6-90FB-3DF181474AE6Q35964678-E7762E09-AF92-41FD-8009-4D7FE7868829Q36124544-36E9A486-1497-49D9-B424-4786C637D06CQ36649277-A8EC9702-C1FE-4CDA-A43D-59C07A667213Q36867463-AC49371C-7FF2-4365-9296-21AE20C5DD8CQ37030680-AB88F0D9-B17A-44E9-A64D-F1BA9F766B25Q37375690-FDBA67C3-583B-4E9F-9CBB-C6F6EEAE36AAQ38177173-E5C8CA6F-6744-4DE0-93DA-3CD25314D0DDQ38200923-01FEB0AC-C401-4923-A55D-8B2D8A34BC5DQ38211881-33C09EB7-981D-446F-AF09-079B4B136B26Q38527885-C2A4CC05-458B-4981-B587-49DA11CAFABBQ38778476-A44BD349-39F4-4755-89CA-25294AEDB32EQ38795046-8D38305C-0AA9-47CD-8456-A81E45DF054AQ39190208-16608B9D-50EC-475D-A0DA-0937FF1053CEQ39870068-5353770E-93C1-472B-BD69-549FF037F4D7Q40803621-9A6311CD-EAB4-4153-B902-6AAC6C2A3536Q41966262-FEC49265-9F03-48A3-A1C4-88C137690F31Q44548336-07633148-7414-416D-812C-11CA5DEA474CQ50876480-BB19ACE8-951D-4EBE-9C5D-CA9BB25491FCQ51226655-A2F7C569-2878-4847-98BE-3D8524EF95F4Q51233383-2FA09EB2-91B4-45E3-A6EB-FCC1B0AEBD55Q51280718-4B43431C-76C7-4BDC-A618-5A1CA28D5828Q51293354-74B62083-99FC-401E-A87F-734920A2890AQ53988383-76F0EB57-7DDA-475F-B36F-32F997F8DA10
P2860
The addition of sitagliptin to ongoing metformin therapy significantly improves glycemic control in Chinese patients with type 2 diabetes.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh-hant
name
The addition of sitagliptin to ...... patients with type 2 diabetes.
@en
The addition of sitagliptin to ...... patients with type 2 diabetes.
@nl
type
label
The addition of sitagliptin to ...... patients with type 2 diabetes.
@en
The addition of sitagliptin to ...... patients with type 2 diabetes.
@nl
prefLabel
The addition of sitagliptin to ...... patients with type 2 diabetes.
@en
The addition of sitagliptin to ...... patients with type 2 diabetes.
@nl
P2093
P2860
P921
P1433
P1476
The addition of sitagliptin to ...... patients with type 2 diabetes.
@en
P2093
Amy O Johnson-Levonas
Barry J Goldstein
Keith D Kaufman
Maria Alba
Samuel S Engel
Wenying Yang
Yanfen Guan
Yue Shentu
P2860
P304
P356
10.1111/J.1753-0407.2012.00213.X
P577
2012-09-01T00:00:00Z